Aspirin
A 120-year-old painkiller, now recommended in low doses to prevent preeclampsia — one of the leading causes of maternal death worldwide.
Act I — The gap
Modern medicine is brilliant.
It is also looking the wrong way.
For most of its history, medical research studied one default patient, and he wasn't a woman. The blind spots this created still cost women time, health, and in some cases lives.
0
The year U.S. law first required women to be included in federally funded clinical trials. Before that, exclusion was routine.
0 of 10
Drugs withdrawn from the U.S. market between 1997–2000 posed greater health risks for women than for men.
~0%
Of healthcare research funding outside oncology goes to conditions specific to women.
0%
Higher likelihood for women to experience an adverse drug reaction — dosing is still largely calibrated to male bodies.
0 years
Average time to an endometriosis diagnosis — a condition affecting roughly 1 in 10 women worldwide.
0%
Of completed clinical trials never publish their results. Negative findings vanish — so mistakes get repeated.
0%
Of new drug candidates fail in development and never reach a single patient.
And the engine that should fix this is slow by design: a single new drug takes 10–15 years and roughly $2.6 billion to reach patients.
Act II — The hidden library
Every approved medicine
is an unfinished story.
Around 9,000 compounds have already earned approval somewhere in the world. Their safety profiles are known. Their chemistry is documented. Most were only ever asked one question. Repurposing asks the next one - and it is dramatically faster and cheaper than starting from zero.
New molecule
10–15 yrs · ~$2.6B
Repurposed compound
3–7 yrs · a fraction of the cost
Repurposed candidates are roughly 3× more likely to reach approval — because the hardest safety questions are already answered.
Metformin
A 1950s diabetes drug under active study for PCOS and gestational diabetes — conditions that waited decades for dedicated research.
Thalidomide
Medicine's darkest lesson, re-examined with rigorous ethics — now a cornerstone treatment for multiple myeloma.
Sildenafil
Developed for angina, famous for something else — and quietly repurposed again to treat pulmonary hypertension.
The answers are on the shelf. What's missing is a way to fund the unglamorous work of asking known compounds new questions. That is exactly what Remedyate is built for.
Act III — What we stand for
The best science shouldn't wait for the biggest return. So we're building a different way to fund it.
Four principles we won't compromise on.
Justice by design
The benefits and burdens of research should be shared fairly. Questions that affect half the world, women's health above all, are a focus here, not a niche.
Radical transparency
Every study we fund commits to publishing its outcome, whether positive, negative or inconclusive. Too often, null and negative results never see daylight. Here, reporting the result is a condition of funding, whatever the result turns out to be.
Patrons get a front-row seat
Most giving goes dark the moment it leaves your hands. Here it doesn't. You follow every milestone and see every result, positive or not, right through to the answer. Watch the science you funded unfold from the front row.
Dignity first
We hold ourselves to the Declaration of Helsinki and the Belmont Report. In practice that means informed consent, independent ethics approval, and one rule we won't bend: no result is ever worth more than a person.
Act IV — Your companion
Meet Clara.
Clara is the intelligence woven through Remedyate. She helps you make sense of everything the platform holds, from how trials work to what's moving in medical research right now, and speaks your language, whether you run studies or fund them.
Act V — Your move
The next breakthrough might not
need to be invented.
Just found.
Fund a study. Join a team. Follow the science from the front row.
Researchers · Patrons · One platform